Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI.3 vs FOLFOX in Gemcitabine-refractory Advanced Pancreatic Cancer
NCT00786006Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Mar 2007
- Primary completion
- Mar 2009
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by Asan Medical Center. Started Mar 2007; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00786006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786006.